Modified Tetracyclines With Reduced Antimicrobial Activity for AUD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for alcohol use disorder (AUD) and other disorders involving inflammatory processes are limited, with few pharmaceutical options and existing tetracycline derivatives primarily focusing on neurodegeneration without addressing addiction or inflammatory aspects.
Innovation Solution
Modified tetracycline molecules with reduced antibacterial and antifungal activity, formulated for oral or parenteral administration, that inhibit Alcohol Use Disorder (AUD), Substance Use Disorder (SUD), pain, and inflammatory disorders by blocking ribosome binding or altering hydrogen bonding, without relying on antibiotic properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If traditional tetracycline derivatives are used to treat neurological conditions, then neurodegenerative effects are addressed, but addiction and inflammatory aspects are not treated
Solution Approach 1:
The patent segments the therapeutic functions by creating separate modified tetracycline derivatives targeting different mechanisms: some derivatives target ribosome binding for addiction treatment, while others target inflammatory pathways. This allows each derivative to be optimized for specific indications without requiring a single complex molecule to address all conditions simultaneously.
Solution Approach 2:
The modified tetracycline derivatives maintain the core tetracycline scaffold which provides broad anti-inflammatory activity, while adding specific modifications that enable additional functions such as ribosome binding inhibition for addiction treatment. This universal scaffold approach allows one class of compounds to address multiple aspects including neurodegeneration, addiction, and inflammation.
2Reliability
If tetracycline derivatives with antibiotic properties are used, then antimicrobial activity is achieved, but antibiotic resistance and side effects occur
Solution Approach 1:
The patent extracts and removes the antibiotic function from the tetracycline scaffold by modifying structures to prevent ribosome binding in bacteria. The modified derivatives retain central nervous system and anti-inflammatory activities while deliberately eliminating the antimicrobial property that causes resistance and gut microbiome disruption.
Solution Approach 2:
The modifications are applied locally at specific positions on the tetracycline ring structure (such as positions 4, 7, or 10) to selectively block bacterial ribosome binding while preserving the ability to cross the blood-brain barrier and interact with human cellular targets. This local modification strategy maintains therapeutic efficacy without the harmful antibiotic effects.
3Ease of operation
If existing treatment methods for alcohol use disorder are used, then some symptomatic relief is provided, but the underlying inflammatory and addictive mechanisms are not addressed
Solution Approach 1:
The modified tetracycline derivatives provide multi-functional treatment by simultaneously addressing inflammatory pathways and addictive mechanisms through a single compound. The derivatives can reduce alcohol consumption, attenuate withdrawal symptoms, and modulate pain sensitization, replacing the need for multiple separate treatments with one versatile agent.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified tetracyclines effectively reduce alcohol consumption, withdrawal symptoms, and pain sensitization, while modulating the central nervous system to treat AUD and SUD, without inducing antibiotic resistance or side effects.
Implementation Method 1
the doxycycline, minocycline, and tigecycline structures are modified to prevent binding of the molecule to a ribosome
Implementation Method 2
the molecule has reduced or substantially no antibacterial activity... the modification at least one of: produces steric hindrance, blocks hydrogen bonding
Data Source
AI summary
The present invention includes novel molecules and methods for using the same to treat Alcohol Use Disorder (AUD), Substance Use Disorder (SUD), tobacco use, pain, or proinflammatory disorders comprising: identifying a subject in need of treatment for at least one of AUD, SUD, pain, or a proinflammatory disorder; and providing the subject with an effective amount of a modified minocycline to ameliorate or eliminate the AUD, SUD, pain, or proinflammatory disorder and that has reduced, or no, antimicrobial activity, wherein the modified tetracycline has a formula, e.g., or the modified doxycycline, minocycline, and tigecycline and their tautomerized structures, where the R-groups shown in the minocycline example above could be different combination of halogen, acetyl ester, methyl ester, and diacetal.